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Tumor necrosis factor alpha (TNF-𝛼) is a cytokine which plays opposing roles in the context of infectious disease pathogenesis.
TNF-𝛼 is essential for the development of a protective immune response to some pathogens, for example, Mycobacterium
tuberculosis, by synergizing with other cytokines. However, exorbitant or uncontrolled TNF-𝛼 activitymay also drive pathology and
disease symptoms in many infectious diseases. In order to elucidate the beneficial and detrimental roles of TNF-𝛼 in tuberculosis
(TB) and other diseases for which the guinea pig is the small animal model of choice, recombinant guinea pig (rgp)TNF-𝛼 has been
produced using prokaryotic expression systems. However, it is unknown whether posttranslational modifications which cannot
be made in the prokaryotic expression systems may be important for rgpTNF-𝛼 structure and function. Therefore, we carried
out a comparative study by expressing rgpTNF-𝛼 in prokaryotic and eukaryotic expression systems and analyzed the eukaryotic-
expressed rgpTNF-𝛼 for the presence of posttranslational modifications by subjecting it to NanoLC-MS/MS. We conclude that
the eukaryotic-expressed rgpTNF-𝛼 lacks posttranslational modifications, and we found no significant difference in terms of the
biological activity between prokaryotic- and eukaryotic-expressed rgpTNF-𝛼. Taken together, results from our study show that a
prokaryotic expression system can be used for generating large amounts of rgpTNF-𝛼 without concern for the biological integrity.
1. Introduction
Tumor necrosis factor alpha (TNF-𝛼) plays important and
contradictory roles in the pathogenesis of many infectious
diseases, including tuberculosis (TB) [1, 2]. TNF-𝛼 synergizes
with other cytokines in contributing to a protective immune
response in the host in TB by promoting the formation and
maintenance of granulomatous lesions which are considered
to be an essential part of the host’s attempts to control both
the local accumulation and dissemination of the pathogen
[3, 4]. Defective granuloma formation was observed in
TNF-deficient mice infected with virulent Mycobacterium
tuberculosis [5]. Humans treated with TNF-blocking drugs
are at high risk of developing reactivation TB, reinforcing the
critical role of TNF-𝛼 in the maintenance of host resistance
[6]. On the other hand, uncontrolled TNF-𝛼 contributes
to disease symptoms (e.g., fever and weight loss), tissue
destruction, and organ pathology in TB and other chronic
diseases [7]. Understanding these apparently contradictory
functions of TNF-𝛼 will require the necessary reagents to
study the molecule in both in vitro and in vivo studies in
the small experimental animals of choice. Animal models
such as mice, guinea pigs, rabbits, and monkeys are widely
used in TB research [8]. The guinea pig model of pulmonary
TB mimics human TB in many important ways, including
the formation of typical, human-like granulomas, and other
characteristic features which makes it a gold standard for
evaluating novel vaccine candidates during preclinical trials
[9]. Our laboratory has cloned and expressed several guinea
pig cytokine and chemokine genes such as interleukin-8
(IL-8/CXCL-8) [10], regulated upon activation, normal T-
cell expressed and secreted (RANTES/CCL5) [11], interferon-
gamma (IFN-𝛾) [12], interleukin-4 (IL-4) [13], interleukin-
10 (IL-10) [14], interleukin-1beta (IL-1beta) [15], monocyte
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chemoattractant protein-1 (MCP-1) [16], and interleukin-17
[17]. We have previously reported the generation of rgpTNF-
𝛼 using a prokaryotic expression system [18] and have used
this reagent to study the contributions of TNF-𝛼 to the
response of both phagocytic cells and whole animals to
infection with virulentM. tuberculosis [19].
The rgpTNF-𝛼 can be produced using either prokaryotic
or eukaryotic expression systems. The advantages of prok-
aryotic expression systems are that a large amount of recom-
binant protein can be produced without the complication
of maintaining large volumes of eukaryotic cell culture and
purifying the protein from a complex matrix composed of
other eukaryotic proteins [19]. On the other hand, eukaryotic
expression systems have the advantage that the proteins pro-
duced may undergo posttranslational modifications which
are required for their structural and biological integrity [20].
Posttranslational modifications were observed in cytokine
and chemokine genes of humans and other species [21, 22].
All of our previous work with rgpTNF-𝛼 has been carried
out with protein produced by E. coli [17, 23]. However,
rgpTNF-𝛼 has not been generated using a eukaryotic expres-
sion system and the impact of posttranslationalmodifications
on the structure and activity of this molecule remains to be
determined. Therefore, in this study, we generated rgpTNF-
𝛼 using an efficient eukaryotic expression system, analyzed
the resulting protein for the presence of posttranslational
modifications, and compared the biological activities of
prokaryotic- and eukaryotic-expressed rgpTNF-𝛼.
2. Materials and Methods
2.1. Prokaryotic Expression of Guinea Pig TNF-Alpha. The
cloning of guinea pig TNF-𝛼 was accomplished by using
the Concanavalin A-stimulated guinea pig splenocytes as
described previously [24]. The construct containing coding
sequence of guinea pig TNF-𝛼 was a generous gift from Dr.
TeizoYoshimura,NationalCancer Institute,USA.Themature
peptide region of guinea pig TNF-𝛼 (accession number-
AF119622) was subcloned into the BamHI and HindIII site of
pQE-30 vector (Qiagen, Chatsworth, CA) and transformed
with M15 competent cells as described previously by our
group [17]. Fresh transformants were obtained by streaking
M15 bacterial culture containing subcloned guinea pigTNF-𝛼
in pQE-30 vector onLuria-Bertini (LB) agar plates containing
100 𝜇g/mL ampicillin (Sigma, St. Louis, MO) and 100𝜇g/mL
kanamycin (Sigma).
One of the transformants was inoculated into 5 milliliter
(mL) of Difco-Luria-Bertini (LB) broth containing appro-
priate antibiotics and grown overnight at 37∘C. 5mL of
the overnight culture was added to 100mL of identical
culture medium in a 250mL flask the following day and was
cultured on a shaker (220 rpm) at 37∘C. When the OD
600
of the culture reached 0.6, protein expression was induced
by adding isopropyl-𝛽-d-thiogalactoside (IPTG; Sigma) to a
final concentration of 1.0mM, followed by incubation for 5
hours at 37∘C.
The cells were harvested by centrifugation and the pellet
was resuspended in 5mL lysis buffer following the manu-
facturer’s instructions [25]. The sample was sonicated and
centrifuged to obtain the cleared lysate that contains rgpTNF-
𝛼.
The cleared lysate was purified by Immobilized Metal
Affinity Chromatography (IMAC) employing the Ni-NTA
matrix (Qiagen) as described previously for other soluble
recombinant guinea pig proteins [15]. All the purification
steps were performed at 4∘C. The nickel-charged Ni-NTA
agarose resin was added to the cleared lysate in a polypropy-
lene column (Qiagen) in a ratio of 1 : 4 and placed on an
orbital shaker for 1 hour. After equilibrating the column with
5mL lysis buffer, the column was subjected to washing twice
with 10mL of wash buffer, followed by final elution of theHis-
tagged protein by the addition of the elution buffer (5mL). A
small fraction of the eluted samples were run on Novex 10–
20% Tricine gel (Invitrogen, Carlsbad, CA) and the gel was
stained with Coomassie brilliant blue. The eluted fractions
containing TNF-𝛼were pooled and concentrated using Ami-
con centrifugal filter devices (Millipore) and the concentrated
protein content was estimated using the Bradford assay kit
(Bio-Rad).
2.2. Eukaryotic Expression of Guinea Pig TNF-𝛼. The eukary-
otic expression vector pCEP-Pu [26] used in this study does
not contain the His tag. In order to add the His tag, the
mature peptide region of TNF-𝛼 cloned into BamHI and
HindIII restriction sites of the pQE-30 vector were amplified
with primer sequences (Invitrogen) designed to contain
NheI/XhoI recognition sequences so that, upon amplification
from the 5󸀠 end, the product contained the NheI flanking
sequence-His tag-mature peptide region of the guinea pig
TNF-𝛼-Xho I flanking sequence. The forward and reverse
primers containing NheI and XhoI recognition sequences
used for amplification were 5󸀠-TAG CTA GCG CAT CAC
CAT CAC CAT CAC GGA-3󸀠 and 5󸀠-TAC TCG AGC AAG
CTT CTA GTT TGT TAA TTT-3󸀠. The italicized parts of
the primer sequences are complementary to the nucleotide
sequences of the guinea pig TNF-𝛼 cDNA whereas the 5󸀠
overhangs (bolded and underlined) are flanking restriction
sites designed to facilitate cloning. The amplified products
were digested with the NheI/XhoI enzymes (New England
Biolabs), and gel eluted prior to ligation with the pCEP-Pu
vector containing the same restriction sites.The ligated prod-
uct was used to chemically transform XL1-Blue competent
cells (Agilent Technologies, Santa Clara, CA) according to the
manufacturer’s instructions and the presence of the inserts in
the transformants was analyzed by restriction analysis with
NheI and XhoI and subjected to Sanger sequencing.
2.3. Transfection of pCEP-Pu Vector Containing the TNF-
𝛼 Gene. Human embryonic kidney (HEK) 293-EBNA cells
(Invitrogen) grown in Dulbecco’s Modified Eagle Medium
(Invitrogen) according to our previously published procedure
[14] were grown to three-fourth confluency and transfected
for 24 h with Lipofectamine 2000 (Invitrogen) using different
concentrations of pCEP-Pu plasmid DNA containing the
gpTNF-𝛼 cDNA.The transfectionmediumwas then replaced
with CD-293 medium without serum containing puromycin
(0.05 𝜇g/mL) and the cells were incubated at 37∘C for 48 h
before collecting the supernatant fluid. Purification of cell
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lysates containing the putative rgpTNF-𝛼 was performed in
a similar manner to that described above for prokaryotic
expressed rgpTNF-𝛼.
2.4. Validation of Eukaryotic Expressed rgpTNF-𝛼 by Western
Blot Analysis. The generation of polyclonal rabbit antiserum
against prokaryotic-expressed rgpTNF-𝛼 has been described
earlier [18]. In brief, the rgpTNF-𝛼 was mixed with the
adjuvant TiterMax Gold (CytRx Corp, Norcross, GA) and
injected subcutaneously into New Zealand white rabbits
in four injections that were spaced at 3-week intervals.
The animals were exsanguinated 5 weeks following the last
booster and sera were collected by centrifugation of blood at
1500 rcf for 20 minutes. The serum was aliquoted and stored
at −80∘C until it was used in the Western blot assay.
Approximately 200 ng of eukaryotic-expressed rgpTNF-
𝛼 protein was run on a 10–20% tricine gel (Invitrogen) and
blotted onto a nitrocellulose membrane using the semidry
Minitrans blot electrophoretic transfer cell apparatus (Bio-
Rad).The identity of the eukaryotic-expressed rgpTNF-𝛼was
determined by its reaction to the polyclonal anti-rgpTNF-𝛼
antiserum by Western blot analysis using the WesternBreeze
chromogenic kit (Invitrogen) following the manufacturer’s
instructions with anti-rabbit (IgG) antibody as the secondary
antibody (Invitrogen).
2.5. LC-MS/MS Analysis of Eukaryotic-Expressed rgpTNF-
𝛼 for Posttranslational Modifications. The eukaryotic-
expressed rgpTNF-𝛼 (approximately 500 nanograms) was
run on a SDS-Tricine gel and the band corresponding to
rgpTNF-𝛼was excised from the gel and subjected to nanoLC-
MS/MS. In silico digestion analysis was performed to judge
the protease best suited for obtaining peptides in the correct
mass range prior to subjecting it to LC-MS/MS [27]. Protein
digests were separated by capillary rp-HPLC prior to in-line
analysis of their masses and fragmentation patterns. Final
data generated were analyzed using Scaffold software (http://
www.proteomesoftware.com/Scaffold/Scaffold viewer.htm).
2.6. Biological Activity of Prokaryotic- and Eukaryotic-
Expressed rgpTNF-𝛼. The biological activity of prokaryotic-
and eukaryotic-expressed rgpTNF-𝛼 was analyzed by mea-
suring their cytotoxicity on L929 fibroblasts as previously
described [28]. In brief, the L929 cell suspension in RPMI
1640 without phenol red and supplemented with 2 𝜇M L-
glutamine, 100 Units of penicillin/mL, 100 𝜇g of strepto-
mycin/mL, and 2% FBS, at a concentration of 4 × 105
cells/mL, were seeded in 100 𝜇L aliquots onto 96-well plates
and incubated at 37∘C overnight in a 5% CO
2
incuba-
tor. The following day, 50𝜇L of serially diluted rgpTNF-𝛼
samples and 50 𝜇L of an 8-𝜇g/mL actinomycin D solution
(final concentration, 2𝜇g/mL) were added to each well
and incubated for an additional 20 h. Tetrazolium reagent
(WST-1; Dojindo, Kumamoto, Japan), and 1-methoxymethyl
phenazinium methyl sulfate (Dojindo) were dissolved at 6
and 0.4mM, respectively, in phosphate-buffered saline (PBS).
These were mixed at a ratio of 1 : 1, and 20 𝜇L was added
to each well. The cells were incubated for 2 hours in a 5%
CO
2
incubator at 37∘C to allow for the color reaction to
develop and the reaction was terminated by adding 25 𝜇L
of 1N sulphuric acid (H
2
SO
4
). The optical density at both
450 nm (OD
450
) and 630 nm (OD
630
) in each well was
measured with a microplate reader for the test and reference
wavelengths. The net change (net OD
450
− OD
630
) for each
well was calculated as follows: net OD
450
−OD
630
= [(OD
450
−
OD
630
of test well) − (OD
450
− OD
630
of TNF-𝛼-treated
control)]. Data obtained was analyzed with a standard curve
generated using recombinant human TNF-𝛼 (R&D Systems
Inc., Minneapolis, Minn.).
3. Results
3.1. Confirmation of Prokaryotic Expressed rgpTNF-𝛼. Upon
streaking on LB plate supplemented with antibiotics, bacte-
rial transformants containing the cloned guinea pig TNF-
𝛼 gene were obtained. Upon induction with IPTG, those
transformants, generated of a protein that was visible as a
17 kDa band on a tricine gel. The rgpTNF-𝛼 protein was
purified under native conditions using Ni-NTA columns,
as the protein was obtained in the soluble form and was
confirmed by its specific binding to antiserum obtained from
rabbits immunized with prokaryotic expressed rgpTNF-𝛼
protein as described previously by our group [18].
3.2. Confirmation of Eukaryotic-Expressed rgpTNF-𝛼. Trans-
formation of pCEP-Pu with the mature peptide region of
the gpTNF-𝛼 gene residing in the pQE-30 vector resulted in
the generation of putative transformants. All five clones that
were randomly selected for restriction digestion analysis con-
firmed the presence of the insert. PlasmidDNA sequencing of
these clones revealed that the TNF-𝛼 sequence was cloned in-
frame with the His tag and thrombin cleavage site of pQE-30
vector from the 5󸀠 end.The culture supernatantswere purified
on NI-NTA columns (Qiagen) to produce a band which was
approximately ∼19 kDa and was identified as a putative 6His-
rgpTNF-𝛼 in the eluted fractions by SDS-PAGE analysis.
Importantly, transfection of HEK-293 EBNA cells with the
empty pCEP-Pu vector (not containing the gpTNF-𝛼 gene
generated using Klenow polymerase) did not generate any
protein band when analyzed on a Coomassie Blue stained
SDS-gel (Figure 1(a)). The eukaryotic expressed rgpTNF-𝛼
was confirmed by its specific and strong binding to antiserum
obtained from rabbits immunizedwith prokaryotic expressed
rgpTNF-𝛼 protein (Figure 1(b)).
3.3. Analysis of Posttranslational Modifications in Eukaryotic-
Expressed rgpTNF-𝛼. The expression of eukaryotic genes
cloned in E. coli lack posttranslational modifications. To
determine whether such modifications were introduced into
rgpTNF-𝛼 by a eukaryotic expression system, the eukar-
yotic-expressed rgpTNF-𝛼 protein was subjected to LC-MS/
MS. Analysis by Proteome software showed that 83% of
the mature peptide region was detected and there are no
posttranslational modifications in those regions (see Table 1
in Supplementary Material available online at http://dx.doi
.org/10.1155/2015/619480). However, intentional modifica-
tions such as carbamidomethylation and deamidation were
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Figure 1: (a) Coomassie blue-stained SDS-PAGE analysis of eukaryotic protein elutions from cells transfected with 18𝜇g of pCEP-Pu plasmid
DNAwithout any gene (vector control) or pCEP-Pu plasmid DNA (18𝜇g) containing TNF-𝛼 gene.The arrow indicates a ∼19 kDa band which
was recognized as rgpTNF-𝛼. Absence of band in the vector control is also shown. MM: molecular marker; V: vector control elutions, and
T: TNF-alpha elutions. (b) Coomassie blue-stained SDS-PAGE analysis of prokaryotic expressed rgp-TNF-𝛼. rgpTNF-𝛼 was expressed using
prokaryotic expression system (pQE-15) and analyzed on SDS-PAGE gel. MM: molecular marker. (c) Identification of eukaryotic expressed
rgpTNF-𝛼 by polyclonal antiserum (1 : 2000 dilution) from immunized rabbits. Approximately 200 nanograms of rgpTNF-𝛼 was run on
10–20% tricine gel and analyzed by western blot analysis for checking its specificity. The ladder was stained with Coomassie Brilliant Blue.
seen (Supplementary Table 1). The carbamidomethylation is
a result of reduction and alkylation. It is an intentional car-
boxymethylation on Cys to prevent reformation of Cys-Cys
disulfides and allow complete denaturation and digestion.
The deamidation is a common artifact of protein purification.
Glutamine, and sometimes asparagines, are easily deami-
dated as is oxidation of methionine (proteins are oxidized
when exposed to oxidizing atmosphere after cell disruption
and the cell is a reducing environment).
3.4. Biological Activity of Prokaryotic- and Eukaryotic-
Expressed rgpTNF-𝛼. Both the prokaryotic- and eukaryotic-
expressed rgpTNF-𝛼 exhibited cytotoxicity on L929 fibrob-
lasts, a standard and widely used assay for TNF-𝛼 biolog-
ical activity [28] (Figure 2). A dose-dependent increase in
cytotoxicity was observed with both of the recombinant
proteins (Figure 2). Importantly, there was no significant
difference in dose-dependent cytotoxicity between prokary-
otic and eukaryotic-expressed rgpTNF-𝛼. Thus, prokaryotic-
expressed rgpTNF-𝛼 is as biologically active as eukaryotic-
expressed rgpTNF-𝛼 at the same concentration in this stan-
dard bioassay.
4. Discussion
This is the first comparative biochemical characterization of
rgpTNF-𝛼 produced in prokaryotic and eukaryotic expres-
sion systems. TNF-𝛼 contributes to both host resistance
and disease pathology in TB and other chronic diseases
[1]. The importance of TNF-𝛼 in the control of latent or
persistent mycobacteria has been revealed by the high risk of
L929 cytotoxicity assay
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Figure 2: Bioactivity of prokaryotic and eukaryotic expressed
guinea pig TNF-𝛼. Prokaryotic and eukaryotic expressed rgpTNF-𝛼
proteins in the concentration ranging from 0 to 10𝜇g/mL were ana-
lyzed for their cytotoxicity on L-929 fibroblasts and the percentage
of cytotoxicity was calculated.
reactivation TB observed in patients undergoing anti-TNF-
therapy for autoimmune diseases [29]. Since approximately
one-third of the world’s population is latently infected with
TB [30] there is immense need to understand the role of
this cytokine in the control of latent infection and precisely
how its pharmacological suppression results in reactivation
of TB. Such an understanding could drive the development
of novel therapeutics which could be used to suppress
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Human MSTESMIRDVELAEEALPKKTGGPQGSRRCLFLSLFSFLIVAGATTLFCLLHFGVIGPQR 60
Chimpanzee MSTESMIRDVELAEEALPKKTGGPQGSRRCLFLSLFSFLIVAGATTLFCLLHFGVIGPQR 60
Dog MSTESMIRDVELAEEPLPKKAGGPPGSRRCFCLSLFSFLLVAGATTLFCLLHFGVIGPQR 60
Cow MSTKSMIRDVELAEEVLSEKAGGPQGSRSCLCLSLFSFLLVAGATTLCCLLHFGVIGPQR 60
Pig MSTESMIRDVELAEEALAKKAGGPQGSRRCLCLSLFSFLLVAGATTLFCLLHFEVIGPQK 60
Mouse MSTESMIRDVELAEEALPQKMGGFQNSRRCLCLSLFSFLLVAGATTLFCLLNFGVIGPQR 60
Rat MSTESMIRDVELAEEALPKKMGGLQNSRRCLCLSLFSFLLVAGATTLFCLLNFGVIGPNK 60
Guinea pig MSTESMIRDVELAEEQLPKKAGGPQGSRRCWCLSLFSFLLVAGATTLFCLLHFGVIGPQR 60
Human
Chimpanzee
Dog
Cow
Pig
Mouse
Rat
Guinea pig
Human ELRDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPC 177
Chimpanzee
Dog ELTDNQLIVPSDGLYLIYSQVLFKGQGCPSTHVLLTHTISRFAVSYQTKVNLLSAIKSPC 177
Cow KLEDNQLVVPADGLYLIYSQVLFRGQGCPSTPLFLTHTISRIAVSYQTKVNILSAIKSPC 177
Pig
Mouse DLKDNQLVVPADGLYLVYSQVLFKGQGCP-DYVLLTHTVSRFAISYQEKVNLLSAVKSPC 179
Rat DLKDNQLVVPADGLYLIYSQVLFKGQGCP-DYVLLTHTVSRFAISYQEKVSLLSAIKSPC 179
Guinea pig GLSDNQLVVPSDGLYLIYSQVLFKGQGCP-SYLLLTHTVSRLAVSYPEKVNLLSAIKSPC 178
Human QRETPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL 233
Chimpanzee QRETPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL 232
Dog QRETPEGTEAKPWYEPIYLGGVFQLEKGDRLSAEINLPNYLDFAESGQVYFGIIAL 233
Cow HRETPEWAEAKPWYEPIYQGGVFQLEKGDRLSAEINLPDYLDYAESGQVYFGIIAL 233
Pig QRETPEGAEAKPWYEPIYLGGVFQLEKDDRLSAEINLPDYLDFAESGQVYFGIIAL 232
Mouse PKDTPEGAELKPWYEPIYLGGVFQLEKGDQLSAEVNLPKYLDFAESGQVYFGVIAL 235
Rat PKDTPEGAELKPWYEPMYLGGVFQLEKGDLLSAEVNLPKYLDITESGQVYFGVIAL 235
Guinea pig QKETPEGAERKPWYEPIYLGGVFQLQKGDRLSAEVNLPQYLDFADSGQIYFGVIAL 234
******************* *** * *****:::*::: :***:***::.**.
******* **** **** ** *** ***** ** ** **:: : *::: :: : *** : ***:: ** .
**** * ** ****** : : ::*::: : :***:*** *. . .. ..
****** ** ***** ***** ********* ******** : :*:: ::*** *** *..
ELRDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPC 176
KLKDNQLVVPTDGLYLIYSQVLFRGQGCPSTNVFLTHTISRIAVSYQTKVNLLSAIKSPC 176
DEKFPNGLPLISSMAQTLTLRSSSQNSSDKPVAHVVANHQVEEQLEWLSQRANALLANGM 120
EEKFPNGLPLISSMAQTLTLRSSSQNSSDKPVAHVVANHQAEEQLEWLSQRANALLANGM 120
EEQFSSGPPFR-PLAQTLTLRSASQNDNDKPVAHVVANQQAEEELQWLSKRANALLANGM 119
EE-FPRDLSLISPLAQAVR--SSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGV 117
EE-FPRDLSLISPLAQAG---SSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGV 116
EE-LPNGLQLISPLAQTVK--SSSRTPSDKPVAHVVANPEAEGQLQWLSRRANALLANGV 117
EE-SPGGPSINSPLVQTLR--SSSQASSNKPVAHVVADINSPGQLRWWDSYANALMANGV 117
EE-FPAGPLSINPLAQGLR--SSSQTS-DKPVAHVVANVKAEGQLQWQSGYANALLANGV 116
Figure 3: Amino acid sequence comparison of TNF-𝛼 from different species showing the presence of conserved putative phosphorylation
sites. Amino acid sequences of human (AAA63207), chimpanzee (ABM91951), Squirrel monkey (AAK92045), Cow (AAA19011), Pig
(AAA74410), Woodchuck (AY253723), Mouse (AAA39275), Rat (AAA41425), and Guinea pig (JN020146) were aligned by EBI Clustal W.
Shading emphasizes identical amino acids and numbers on the right represent the position of amino acid.
the detrimental effects of TNF-𝛼 in autoimmune diseases
without interfering with the essential host defense mecha-
nisms that keepM. tuberculosis in check [31]. Such studieswill
benefit greatly from the availability of small animal models
in which detailed mechanistic investigations of TNF-𝛼 at the
molecular and cellular level can be conducted.The guinea pig
is widely accepted to be the small animal model of choice for
TB, however, knowledge of the basic biology of guinea pig
cytokines and reagents with which to study them are only
now developing [32].
In our work by us and others, the function of gpTNF-
𝛼 was examined in a series of studies in which rgpTNF-𝛼
and polyclonal antisera were used to enhance or suppress,
respectively, the cytokine’s functions ex vivo in guinea pig
phagocytic cells or in vivo in whole animals infected with
virulent M. tuberculosis [7, 17, 18, 24]. The choice of a
prokaryotic expression system for those early studies was
based upon the advantages of ease ofmanipulation of bacteria
versus eukaryotic cells, and the high yield of protein [20].
While those studies yielded important new information
about the contributions of TNF-𝛼 to TB resistance, there was
always a concern that the prokaryotic-expressed rgpTNF-𝛼
did not contain posttranslational modifications which might
be important for TNF-𝛼 function in the guinea pig.Therefore,
we undertook the task of expressing rgpTNF𝛼 in a eukaryotic
expression system and examining the protein for such modi-
fications.
Posttranslational modifications have significant effects
on the structure and function of many mammalian pro-
teins [33, 34]. No published information is available on the
posttranslational modification of any guinea pig protein.
Posttranslational modifications are reported to exert signif-
icant effect on the activity of cytokine proteins [35, 36]. In
recombinant TNF-𝛼 from humans, mice and rats, three of
the five potential posttranslational modification sites are in
the signal peptide region, where as the other two are in the
mature peptide region. (http://www.phosphosite.org/protein-
Action.do?id=8542247&showAllSites=true). Interestingly, all
the five potentially phosphorylated amino acids are also
conserved in the guinea pig (second, third, and fifth amino
acids -S, T, S) as well as other mammalian species (Figure 3).
However, since the mature peptide region was cloned with-
out the need for the signal peptide region, the first three
modifications were not observed. Peptides corresponding
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to the last two modifications were obtained in our analysis
but posttranslational modifications were not observed in our
analysis.
We observed no posttranslational modifications in our
eukaryotic-expressed rgpTNF-𝛼 and no difference in the
dose-dependent biological function in the standard L929
cell cytotoxicity assay (Figure 2; Supplementary Table 1). In
addition, rabbit polyclonal antisera developed in response to
prokaryotic-expressed rgpTNF𝛼 cross-reacted strongly with
the eukaryotic-expressed protein (Figure 1). Additional work
with the recombinant proteins, including another functional
assay to validate these findings, was not possible because the
laboratory in which these studies were performed has closed
due the retirement of the principal investigator.Thus, we con-
clude that the prokaryotic expressed rgpTNF-𝛼 can be used
in future studies without concern that the expression system
has failed to introduce modifications which alter the protein’s
biological function significantly. The prokaryotic expression
system is preferred because of the ease of manipulation and
the relatively higher yield. In studies comparing the yield of
rgpTNF-𝛼 in the two expression systems, we observed at least
20-fold increase in the protein yield from E. coli compared to
the HEK cells (Data not shown). Given the importance of the
guinea pig as a small animal model of TB and other diseases
[37, 38], we believe that our observations will facilitate future
studies of the role of TNF-𝛼 using recombinant protein
expressed in prokaryotic systems.
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